https://www.selleckchem.com/products/MK-2206.html
Although add-on transcranial direct current stimulation (tDCS) is a promising intervention for treating unipolar (UD) and bipolar depression (BD), its moderate antidepressant efficacy urges research into biomarkers for predicting therapeutic response and achieving highly targeted applications. This open-label trial enrolled UD (N=58) and BD (N=22) patients who had failed 1 or more trials of adequate pharmacologic interventions (ClinicalTrials.gov ID NCT03287037). Bifrontal tDCS (anode/cathode F3/F4) was applied using a 2 mA current for
Like
Comment
Share
